- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04578444
Um Protocolo de Tratamento de Acesso Expandido de Zanidatamab (ZW25) em Pacientes com Câncer Avançado do Trato Biliar HER2-Positivo
Uso de Acesso Expandido de Zanidatamab para o Tratamento de Tumor Sólido Avançado HER2-Positivo
This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Tipo de acesso expandido
- População de tamanho intermediário
Contactos e Locais
Locais de estudo
-
-
-
Barcelona, Espanha, 08035
- Vall D'Hebron University Hospital
-
Madrid, Espanha, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Espanha, 28040
- Fundacion Jimenez Diaz University Hospital - Autonomous University of Madrid
-
-
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- NoCo Banner MD Anderson Cancer Center
-
-
California
-
Cerritos, California, Estados Unidos, 90603
- TOI Clinical Research
-
Salinas, California, Estados Unidos, 93901
- Salinas Valley Memorial Healthcare System
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
-
-
-
Besançon, França, 25030
- Jean Minjoz Hospital
-
Marseille, França, 13385
- Hopital Timone Marseille
-
Pessac, França, 33604
- Hopital Haut-Leveque - CHU Bordeaux
-
Villejuif, França, 94805
- Gustave Roussy Cancer Center
-
-
-
-
-
Candiolo, Itália, 10060
- ICCRS Candiolo
-
Milan, Itália, 20133
- Istituto Nazionale Tumori
-
Milan, Itália, 20072
- Istituto Clinico Humanitas
-
-
-
-
-
Harlow, Reino Unido, CM20 1QX
- The Princess Alexandra Hospital NHS Trust (Joanne Kwa, Pharmacist)
-
London, Reino Unido, WC1E 6AG
- UCLH Cancer Institute (Meera Desai, Pharmacist)
-
London, Reino Unido, WC1E 6JA
- HCA Healthcare UK
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed HER2-positive locally advanced or metastatic biliary tract cancer that has progressed after receipt of available therapies known to confer clinical benefit.
- Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50%
- Adequate organ function
- Ineligible to participate or has no access to an ongoing zanidatamab or other Zymeworks clinical study (e.g., ZW49 clinical study).
- Females of childbearing potential and non-sterile males must agree to practice highly effective methods of birth control for the duration of the study and for 12 months after the last dose of study drug. In addition, non-sterile males must avoid sperm donation for the duration of the study and for 12 months after the last dose of study drug.
Exclusion Criteria:
-
Participating in other studies involving investigational drug(s) ≤ 3 weeks before the first dose of zanidatamab.
-
Systemic anti-cancer therapy ≤ 3 weeks before the first dose of zanidatamab.
-
Radiotherapy ≤ 2 weeks of the first dose of zanidatamab
-
The following central nervous system (CNS) brain lesions are excluded from the study:
-
Untreated or unstable brain lesions requiring immediate local therapy or symptomatic CNS metastases.
-
Radiation treatment for CNS metastases within 4 weeks before the first dose of zanidatamab.
-
Known history of or ongoing leptomeningeal disease (LMD). If LMD has been reported radiographically, but is not suspected clinically by the investigator, the patient must be free of neurological symptoms of LMD.
-
The following CNS brain lesions are permitted:
- Stable brain lesions are permitted if stable, as defined by patients who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening.
-
-
Concurrent uncontrolled or active hepatobiliary disorders or untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, unresolved biliary obstruction, biloma or abscess. Any complications should be resolved within 2 weeks prior to the first dose of zanidatamab.
-
Active hepatitis
-
Infection with human immunodeficiency virus (HIV) with uncontrolled disease.
-
Females who are breastfeeding or pregnant, and females and males planning a pregnancy.
-
History of myocardial infarction or unstable angina within 6 months prior to enrollment, congestive heart failure (NYHA Class 3 or 4), or clinically significant cardiac disease
-
QTc Fridericia (QTcF) > 470 ms assessed within 30 days of screening
-
Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease
Plano de estudo
Como o estudo é projetado?
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ZWI-ZW25-EAP
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .